TrialEuropean journal of heart failure2021

Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.

Jawad H Butt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.